Daiichi Sankyo Company, Limited (TYO: 4568)
Japan
· Delayed Price · Currency is JPY
4,450.00
+33.00 (0.75%)
Jan 21, 2025, 3:30 PM JST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 446.55B JPY in the quarter ending September 30, 2024, with 18.92% growth. This brings the company's revenue in the last twelve months to 1.76T, up 25.84% year-over-year. In the fiscal year ending March 31, 2024, Daiichi Sankyo Company had annual revenue of 1.60T with 25.28% growth.
Revenue (ttm)
1,758.07B
Revenue Growth
+25.84%
P/S Ratio
4.84
Revenue / Employee
93.88M
Employees
18,726
Market Cap
8,361.23B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
Mar 31, 2020 | 981.79B | 52.08B | 5.60% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,142.35B |
HOYA Corporation | 812.74B |
Takeda Pharmaceutical Company | 4,546.08B |
Otsuka Holdings | 2,269.56B |
Terumo | 986.67B |
Astellas Pharma | 1,772.16B |
Olympus | 973.60B |
Shionogi & | 418.51B |
Daiichi Sankyo Company News
- 3 days ago - DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer - Benzinga
- 3 days ago - DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer - Benzinga
- 3 days ago - AstraZeneca, Daiichi Sankyo antibody-drug conjugate Dato-DXd gains FDA nod - Seeking Alpha
- 6 days ago - AstraZeneca (AZN) and Daiichi Sankyo's ADC Drug Gains Priority Review by FDA - GuruFocus
- 7 days ago - Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH - Business Wire
- 11 days ago - High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower - Seeking Alpha
- 24 days ago - Daiichi Sankyo gets Japanese approval for Datroway - Seeking Alpha
- 4 weeks ago - Astra, Daiichi Withdraw EU Application for Lung Cancer Drug - BNN Bloomberg